Supernus Pharmaceuticals Inc (NASDAQ:SUPN)
| 6.00 Data as of May 17 |  +0.16 / +2.74%Today’s Change | 4.30 Today|||52-Week Range 16.68 | -16.32% Year-to-Date |
Latest SUPN News | Press Releases
| 5 Stocks Setting Up to Break Out May 17 / TheStreet.com | Narrower-than-Expected Loss at Supernus - Analyst Blog May 14 / Zacks.com |
| 8 Stocks Under $10 Trending Sharply Higher May 14 / TheStreet.com |
Today’s Trading
| Previous close | 5.84 |
| Today’s open | 6.04 |
| Day’s range | 5.81 - 6.09 |
| Volume | 927,579 |
| Average volume (3 months) | 446,410 |
| Market cap | $185.9M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -165.83% |
| Earnings growth (this year) | +9.43% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +84.31% |
| P/E ratio | NM |
| Price/Sales | 84.49 |
| Price/Book | 3.19 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VNDAVanda Pharmaceutical... | +1.08 | +19.64% |
| AMPEAmpio Pharmaceutical... | +0.03 | +0.60% |
| ACSTAcasti Pharma Inc | 0.00 | 0.00% |
| DRTXDurata Therapeutics ... | -0.01 | -0.14% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Last reporting date | May 14, 2013 |
| EPS forecast (this quarter) | -$0.60 |
| Annual revenue (last year) | $1.5M |
| Annual profit (last year) | -$46.3M |
| Net profit margin | -3,127.30% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Jack A. Khattar, MBA |
CFO, Vice President & Head-Investor Relations Gregory S. Patrick, MBA |
Corporate headquarters Rockville, Maryland |
Forecasts
